股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年3月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 天安卓健有限公司 | | | | | | 呈交日期: | 2026年4月1日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | 300,000,000 | | 增加 / 減少 (-) | | | | | | ...

1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公佈僅供參考，並不構成收購、購買或認購天安卓健有限公司證券的邀請或要約，亦不構成在任 何司法管轄區招攬任何投票或批准。本公佈不得在任何司法管轄區內發佈、刊發或派發，倘於該等 司法管轄區內進行上述行為將構成違反其相關法律法規。 （於百慕達註冊成立之有限公司） （股份代號：383） MEDICARE 委任獨立財務顧問 本公佈乃根據收購守則規則2.1而作出。 茲提述天安卓健有限公司（「本公司」）於二零二六年三月二十三日刊發的公告 （「該公佈」），內容有關（其中包括）由萬基證券有限公司代表本公司提出有條件現 金要約按每股股份港幣1.1元回購最多達70,000,000股股份。除文義另有所指外，本公 佈所用之詞彙與該公佈所界定者具有相同涵義。 董事會宣佈，旭倫企業融資有限公司，一間根據證券及期貨條例可從事第六類（就機 構融資提供意見）受規管活動之持牌法團，已獲本公司委任為獨立財務顧問，以就要 約是否屬公平合理 ...

董事會宣佈萬基證券將代表本公司提出要約，在該條件的規限下，按每股股份港 幣1.1元的價格回購並註銷最多達最高數目的股份（即70,000,000股股份，佔於本公 佈日期已發行股份約6.48%）。要約將於全面遵守股份回購守則下提出。要約代價 （倘要約獲全面接納，即合共為港幣77,000,000元）將以現金支付，並將以本集團 的內部資源撥付。百利勤金融（本公司之財務顧問）確認，本公司擁有充裕的財務 資源，可根據本公佈所述之要約條款滿足要約獲全面接納所需之資金。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公佈乃根據並為符合香港聯合交易所有限公司證券上市規則、收購守則及股份回購守則而編製， 並不構成要約購買或招攬要約出售或認購任何證券或邀請訂立協議以作出任何該等事宜，亦並非旨 在邀請要約購買、出售或認購任何證券。 （於百慕達註冊成立之有限公司） （股份代號：383） MEDICARE (1)萬基證券有限公司代表天安卓健有限公司提出 有條件現金要約按每股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 MEDICARE （於百慕達註冊成立之有限公司） （股份代號：383） 短暫停牌 天安卓健有限公司（「本公司」）董事會（「董事會」）謹此公佈，應本公司要求，本公司 之股份（股份代號：383）將於二零二六年三月十六日（星期一）上午九時正起短暫 停止買賣，以待根據公司收購、合併及股份回購守則發出載有本公司內幕消息之公 佈。 代表董事會 天安卓健有限公司 執行董事 江木賢 香港，二零二六年三月十六日 於本公佈日期，董事會包括執行董事江木賢先生及郭美保先生；非執行董事李成輝先生（主席）、 王大鈞先生、周海英先生、高兆元先生及張園園女士；及獨立非執行董事夏曉寧博士、王永權博士、 楊麗琛女士及曹丹先生。 ...

Financial Performance - The company's total revenue for the year ended December 31, 2025, was HKD 1,638,180,000, a slight increase of 0.7% from HKD 1,627,199,000 in 2024[3] - Gross profit decreased to HKD 309,548,000 in 2025, down 8.0% from HKD 336,220,000 in 2024[4] - Operating profit significantly declined to HKD 21,904,000, a decrease of 74.6% compared to HKD 86,118,000 in the previous year[4] - The company reported a net loss of HKD 20,806,000 for 2025, compared to a profit of HKD 41,976,000 in 2024[4] - Basic loss per share was HKD 2.48, compared to earnings of HKD 2.65 per share in the previous year[4] - The group reported a consolidated loss before tax of HKD 469,000 for the year ended December 31, 2025, compared to a profit of HKD 57,004,000 in 2024, indicating a decline in profitability[16] - The company reported a net loss attributable to shareholders of HKD 26,816,000 for 2025, compared to a profit of HKD 28,773,000 in 2024[27] - The company recorded a loss attributable to shareholders of HKD 26,816,000 for 2025, a significant decline from a profit of HKD 28,773,000 in 2024[34] Assets and Liabilities - Total assets as of December 31, 2025, were HKD 3,548,534,000, a decrease from HKD 3,538,877,000 in 2024[6] - Current liabilities increased to HKD 1,183,728,000 in 2025 from HKD 1,165,696,000 in 2024[7] - The company's net asset value decreased to HKD 1,858,740,000 in 2025 from HKD 1,894,829,000 in 2024[7] - The company's net asset value per share was HKD 1.64 as of December 31, 2025, down from HKD 1.67 in 2024[35] - The total borrowings of the group reached HKD 891,666,000 as of December 31, 2025, compared to HKD 833,383,000 in 2024, with secured bank borrowings increasing to HKD 138,314,000 from HKD 35,123,000[65] Revenue Segments - Revenue from customer contracts for the year ended December 31, 2025, was HKD 1,630,706,000, a slight increase from HKD 1,620,606,000 in 2024, representing a growth of approximately 0.67%[13] - The healthcare segment generated revenue of HKD 1,582,283,000, contributing significantly to the overall revenue, while the elderly care segment reported revenue of HKD 51,463,000[16] - Revenue from property investment was HKD 4,279,000, while property development generated HKD 155,000, indicating limited contributions from these segments[16] - The elderly care segment reported a loss of HKD 107,195,000, highlighting challenges in this area compared to the healthcare segment's profit of HKD 119,077,000[16] - The revenue from the elderly care division increased to HKD 51,463,000, up from HKD 41,827,000 in the previous year, despite a recorded loss of HKD 107,195,000[47] Financial Adjustments and Standards - The company has adopted new accounting standards effective from January 1, 2025, which did not have a significant impact on its financial position or performance[9] - The group anticipates that the adoption of the new Hong Kong Financial Reporting Standards will not have a significant impact on its financial performance and position, although it may affect the structure and presentation of the consolidated income statement[12] - The group expects to implement new accounting standards starting from January 1, 2027, with early adoption permitted, and is currently evaluating the specific impacts on its consolidated financial statements[12] - The group is assessing the impact of the new financial reporting standards on its consolidated financial statements, indicating a proactive approach to compliance and financial transparency[12] Operational Highlights - The company is focusing on enhancing medical technology management and optimizing service processes to improve operational efficiency[39] - Both hospitals will integrate advanced medical technologies and minimally invasive procedures to improve specialty capabilities and patient satisfaction, with a focus on areas like cardiology and chronic disease management[77] - The healthcare division will focus on enhancing service quality and operational efficiency, implementing cost reduction strategies to ensure effective daily operations[76] - The elderly care division aims to enhance quality, efficiency, and scale by 2026, with a goal to establish a reliable health community in Qingpu District, Shanghai[79] Governance and Leadership - The board of directors includes executive directors Jiang Muxian and Guo Meibao, and non-executive directors including Li Chenghui (Chairman) and Wang Dajun[89] - The independent non-executive directors consist of Dr. Xia Xiaoning, Dr. Wang Yongquan, Ms. Yang Lichen, and Mr. Cao Dan[89] - The company is focused on enhancing governance with a diverse board composition[89] - The presence of independent directors suggests a commitment to transparency and accountability in operations[89] - The governance structure is designed to support effective oversight and strategic direction[89] Shareholder Actions - The company recognized a dividend of HKD 21,663,000 for the year 2025, compared to HKD 10,860,000 in 2024[25] - The board does not recommend a final dividend for the year ending December 31, 2025, maintaining a cautious approach amid geopolitical and economic uncertainties[82][81] - The company repurchased a total of 3,970,000 shares at a total cost of HKD 3,504,550 during the year, with all repurchased shares subsequently canceled[87] - The repurchase details include a peak price of HKD 1.03 per share and a minimum price of HKD 0.74 per share across various months[88]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 MEDICARE （於百慕達註冊成立之有限公司） （股份代號：383） 盈利警告 本公佈乃由天安卓健有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例 第571章證券及期貨條例第X IVA部項下之內幕消息條文（定義見上市規則）而作 出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據其 對本集團截至二零二五年十二月三十一日止年度之相關未經審核綜合管理賬目之 初步審閱及目前可得資料，視乎任何進一步減值調整、公允價值變動及╱或物業 之撥備調整或其他調整，本集團預期於截至二零二五年十二月三十一日止年度錄 得股東應佔虧損估計介乎約15,000,000港元至45,000,000港元之間，相比截至二零 二四年十二月三十一日止年度的股東應佔溢利約28,800,000港元。此乃主要由於(i) 投資物 ...

承董事會命 天安卓健有限公司 公司秘書 薛寶鈴 香港，二零二六年三月三日 於本公佈日期，董事會由執行董事江木賢先生及郭美保先生；非執行董事李成輝先生（主席）、 王大鈞先生 、 周海英先生、 高兆元先生 及張園園女士 ； 以 及獨立非執行董事夏曉寧博士、 王永權博士、楊麗琛女士及曹丹先生組成。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：383） 董事會會議召開日期 天安卓健有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司將於二零二六 年三月十三日（星期五）舉行董事會會議，藉以（其中包括）批准本公司及其附屬公 司截至二零二五年十二月三十一日止年度之全年業績及其刊發，以及考慮派發股息 （如有）。 ...

呈交日期: 2026年3月2日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 公司名稱: 天安卓健有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00383 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | 本月底法定/註冊股本總額： HKD 300,000,0 ...

Group 1 - The company reported a capital expenditure of $12.29 billion for the last fiscal year [1]

Core Insights - The company reported a full-year underlying profit of $10.87 billion, slightly exceeding the forecast of $10.81 billion [1] Financial Performance - The reported underlying profit of $10.87 billion indicates a strong financial performance for the year, surpassing market expectations [1]